America should pressure wealthy allies to contribute more to pharmaceutical innovation — not import the very price controls that made those countries dependent on American innovation in the first place.
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount.
President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative medicines. Unsurprisingly, many of them are furious.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
Sally C. Pipes
America should pressure wealthy allies to contribute more to pharmaceutical innovation — not import the very price controls that made those countries dependent on American innovation in the first place.
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount.
President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative medicines. Unsurprisingly, many of them are furious.
That’s a sign that the strategy is working.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.